IP Library › Granted Patent US 12,458,675
Granted Patent B2
US 12,458,675 · App. 18/641,861 · Granted Nov 4, 2025

Compositions and methods for treating and managing chronic inflammatory skin disorders

Inventors: Marc Cornell (San Jose, CA); Barbara A. Paldus (San Jose, CA)
Assignee: CODEX LABS CORPORATION
A61K36/30A61K9/0014A61K36/185A61K36/28A61K47/18A61K47/36A61P17/18A61P29/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,458,675
App. No.
18/641,861
Granted
Nov 4, 2025
Kind
B2
Abstract

The present invention is directed to compositions and methods for treating and managing symptoms associated with inflammatory skin disorders by applying a synergistic blend of plant-based actives containing at least: (a) Calendula officinalis stem cell extract; (b) Symphytum officinale extract; and (c) a biotech-derived Haberlea rhodopensis extract.

Claims (20)

1 . A composition for application onto human skin comprising a synergistic blend of at least: (a) Calendula officinalis extract; (b) Symphytum officinale extract; and (c) Haberlea rhodopensis extract, wherein the composition is capable of effectively treating and managing symptoms associated with inflammatory skin disorders, and wherein (a), (b), and (c) are employed in a ratio by weight of about 2:1:1, respectively.

2 . The composition of claim 1 , wherein (a) is present in an amount of from about 0.1 to about 5.0% by weight, (b) is present in an amount of from about 0.1 to about 5.0% by weight, and (c) is present in an amount of from about 0.1 to about 5.0% by weight, all weights based on total weight of the composition.

3 . The composition of claim 1 , wherein (a) is present in an amount of from about 0.15 to about 3.5% by weight, (b) is present in an amount of from about 0.15 to about 3.5% by weight, and (c) is present in an amount of from about 0.15 to about 3.5% by weight, all weights based on total weight of the composition.

4 . The composition of claim 1 wherein (a) is present in an amount of from about 0.20 to about 2.0% by weight, (b) is present in an amount of from about 0.20 to about 2.0% by weight, and (c) is present in an amount of from about 0.25 to about 2.0% by weight, all weights based on total weight of the composition.

5 . The composition of claim 1 , further comprising at least one humectant.

6 . The composition of claim 5 , wherein the at least one humectant is present in an amount of from about 0.1 to about 10% by weight, based on total weight of the composition.

7 . The composition of claim 5 , wherein the at least one humectant comprises hyaluronic acid.

8 . The composition of claim 1 , further comprising at least one ceramide.

9 . The composition of claim 8 , wherein the at least one ceramide is present in an amount of from about 0.01 to about 1.0% by weight, based on total weight of the composition.

10 . The composition of claim 8 , wherein the at least one ceramide is selected from ceramide 1, ceramide 2, ceramide 3, ceramide 4, ceramide 5, ceramide 1A, ceramide 6 II, ceramide AP, ceramide EOP, ceramide EOS, ceramide NP, ceramide NG, ceramide NS, ceramide AS, and ceramide NS dilaurate.

11 . A composition for application onto human skin comprising: (1) a synergistic blend of at least: (a) Calendula officinalis stem cell extract, (b) Symphytum officinale extract, and (c) a biotech-derived Haberlea rhodopensis extract; (2) at least one humectant; and (3) at least one ceramide, wherein the composition is capable of effectively treating and managing symptoms associated with inflammatory skin disorders, and wherein (a), (b), and (c) are employed in a ratio by weight of about 2:1:1, respectively.

12 . The composition of claim 11 , wherein (a) is present in an amount of from about 0.1 to about 5.0% by weight, (b) is present in an amount of from about 0.1 to about 5.0% by weight, (c) is present in an amount of from about 0.1 to about 5.0% by weight, (2) is present in an amount of from about 0.1 to about 10% by weight, and (3) is present in an amount of from about 0.01 to about 1.0% by weight, all weights based on total weight of the composition.

13 . The composition of claim 11 , wherein (a) is present in an amount of from about 0.20 to about 2.0% by weight, (b) is present in an amount of from about 0.20 to about 2.0% by weight, (c) is present in an amount of from about 0.20 to about 2.0% by weight, (2) is present in an amount of from about 0.1 to about 5.0% by weight, and (3) is present in an amount of from about 0.1 to about 0.3% by weight, all weights based on total weight of the composition.

14 . The composition of claim 11 , wherein the composition is free of a skin-sensitizing amount of an essential oil and has a pH ranging from about 4.5 to about 5.5.

15 . The composition of claim 1 , wherein each of (a), (b), and (c) comprises an oil infusion.

16 . The composition of claim 11 , wherein each of (a), (b), and (c) comprises an oil infusion.

17 . A method of treating and managing symptoms associated with inflammatory skin disorders comprising applying an effective amount of the composition of claim 1 onto skin of a subject in need thereof.

18 . The method of claim 17 , wherein the symptoms include at least one of a compromised skin barrier, inflammation, and oxidative stress.

19 . A method of reducing reliance on corticosteroids comprising applying an effective amount of the composition of claim 1 onto skin of a subject in need thereof.

20 . The method of claim 19 , wherein the subject exhibits symptoms including at least one of a compromised skin barrier, inflammation, and oxidative stress.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2024
From: CORNELL, MARC; PALDUS, BARBARA A.
To: CODEX LABS CORPORATION
Reel/Frame 067671/0682 →
Continuity (1)
Related Publication 20250325613A1 · Oct 23, 2025
References Cited (60)
US 10682306B1 · Ryan et al. · 2020 [cited by applicant]
US 10721937B1 · Cornell et al. · 2020 [cited by applicant]
US 20070048243A1 · Hansenne et al. · 2007 [cited by applicant]
US 20080014162A1 · Willemin et al. · 2008 [cited by applicant]
US 20150118334A1 · Rozenblat · 2015 [cited by applicant]
US 20160256368A1 · Santhanam et al. · 2016 [cited by applicant]
US 20190111093A1 · Siurkus et al. · 2019 [cited by applicant]
US 20220110845A1 · Plows · 2022 [cited by applicant]
US 20230248798A1 · Webb · 2023 [cited by applicant]
US 20240115643A1 · Franklin · 2024 [cited by applicant]
US 20240358787A1 · Chen et al. · 2024 [cited by applicant]
BG 3819U1 · 2020 [cited by applicant]
JP 5465037B2 · 2014 [cited by applicant]
WO 2012033422A1 · 2012 [cited by applicant]
WO 2018178712A1 · 2018 [cited by applicant]
WO 2024098120A1 · 2024 [cited by applicant]
Mihaylova et al. (2011) J. Food Biochem. 37(3): 255-261. (Year: 2011). [cited by examiner]
Chen et al. (2018) Industrial Crops & Prods. 121: 18-25 (Year: 2018). [cited by examiner]
Meckfessel et al. (2014) J. Am. Acad. Dermatol. 71: 177-184 (Year: 2014). [cited by examiner]
Preethi et al. (2006) Pharmaceutical Biology 44: 9, 691-697. (Year: 2006). [cited by examiner]
Raskin et al. (2004) Current Pharmaceutical Design 10, 3419-3429. (Year: 2004). [cited by examiner]
Revilla et al. (1998) J. Agric. Food Chem. 46: 4592-4597. (Year: 1998). [cited by examiner]
Seigner et al. (2019) Frontiers in Pharmacology vol. 10, Article 289 (12 pages) (Year: 2019). [cited by examiner]
Sowa et al. (2017) Natural Product Research 32(5): 605-609. (Year: 2017). [cited by examiner]
Tallarida (2011) Genes & Cancer 2(11): 1003-1008. (Year: 2011). [cited by examiner]
Bang et al., “Integrated bioinformatic analysis of gene expression profiling data to identify combinatorial biomarkers in inflammatory skin disease,” Sci. Report 12: 5889 (2022). [cited by applicant]
Blunder et al., “PPARdelta in affected atopic dermatitis and psoriasis: a possible role in metabolic programming,” Int. J. Mol. Sci. 22(14): 7354 (2021). [cited by applicant]
Boudjadi et al., “The expression and function of PAX3 in development and disease,” Gene 666: 145-157 (2018). [cited by applicant]
Budu-Aggrey et al., “European and multi-ancestry genome-wide association meta-analysis of atopic dermatitis highlights importance of systemic immune regulation,” Nature Comm. 14: 6172 (2023). [cited by applicant]
Coleman et al., “Rho GTPase signalling pathways in the morphological changes associated with apoptosis,” Cell Death Differ. 9: 493:504 (2002). [cited by applicant]
Costanzo et al., “The Biology and Function of Tissue Inhibitor of Metalloproteinase 2 in the Lungs,” Pulm. Med. 2022:3632764 (2022). [cited by applicant]
Edamitsu et al., “AHR and NRF2 in Skin Homeostasis and Atopic Dermatitis,” Antioxidants 11(2):227 (2022). [cited by applicant]
Facheris et al., “The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment,” Cell Mol. Immunol. 20: 448-474 (2023). [cited by applicant]
Fania et al., “Multiple roles for cytokines in atopic dermatitis: from pathogenic mediators to endotype-specific biomarkers to therapeutic targets,” Int. J. Mol. Sci. 23(5): 2684 (2022). [cited by applicant]
Fujii, “The Pathogenic and Therapeutic Implications of Ceramide Abnormalities in Atopic Dermatitis,” Cells 10(9): 2386 (2021). [cited by applicant]
Gordon et al., “A novel pathogenic variant in the corneodesmosin gene causing generalized inflammatory peeling skin syndrome with marked eosinophilia and trichorrhexis invaginate,” Pediatr. Dermatol. 39(2): 268-272 (202… [cited by applicant]
Ishida-Yamamoto et al., “The biology and regulation of corneodesmosomes,” Cell Tissue Res. 360(3): 477-482 (2015). [cited by applicant]
Ito et al., “Biology of Hsp47 (Serpin H1), a collagen-specific molecular chaperone,” Seminar Cell Dev. Biol. 62: 142-151 (2017). [cited by applicant]
Klein et al., “GRHL3 binding and enhancers rearrange as epidermal keratinocytes transition between functional states,” PLOS Genet. 13(4): e1006745 (2017). [cited by applicant]
Kulišić et al., “Immunohistochemical Analysis of Adhesion Molecules E-Selectin, Intercellular Adhesion Molecule-1, and Vascular Cell Adhesion Molecule-1 in Inflammatory Lesions of Atopic Dermatitis,” Life 13: 933 (2021). [cited by applicant]
Medic et al., “Differential PAX3 functions in normal skin melanocytes and melanoma cells,” Biochem. Biophys. Res. Comm. 411(4): 832-837 (2011). [cited by applicant]
Nakahara et al., “Potential role of endothelin-1 in atopic dermatitis,” Curr Treat. Options Allergy 6: 156-163 (2019), Abstract. [cited by applicant]
Nomura et al., “Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes,” J. Immunol. 171(6): 3262-3269 (2003). [cited by applicant]
Park et al., “A novel endogenous damage signal, CSF-2, activates multiple beneficial functions of adipose tissue-derived mesenchymal stem cells,” Mol. Therapy 27(6):1087-1100 (2019). [cited by applicant]
Salminen, “Aryl hydrocarbon receptor (AhR) reveals evidence of antagonistic pleiotropy in the regulation of the aging process,” Cell. Mol. Life Sci. 79: 489 (2022). [cited by applicant]
Serveaux-Dancer et al., “Pathological Implications of Receptor for Advanced Glycation End-Product (AGER) Gene Polymorphism,” Dis. Markers 2019: 6067353 (2019). [cited by applicant]
Tsybikov et al., “Plasma endothelin-1 levels during exacerbation of atopic dermatitis,” Allergy Asthma Proc. 36(4): 320-324 (2015). [cited by applicant]
Tyavambiza et al., “Cellular and Molecular Events of Wound Healing and the Potential of Silver Based Nanoformulations as Wound Healing Agents,” Bioengineering 9(11): 712 (2022). [cited by applicant]
Wagener et al., “Targeting the redox balance in inflammatory skin conditions,” Int. J. Mol. Sci. 14(5): 9126-9167 (2013). [cited by applicant]
Werfel, “The role of leukocytes, keratinocytes, and allergen-specific IgE in the development of atopic dermatitis,” J. Invest. Dermatol. 129(8): 1878-1891 (2009). [cited by applicant]
Zheng et al., “A novel function of NLRP3 independent of inflammasome as a key transcription factor of IL-33 in epithelial cells of atopic dermatitis,” Cell Death Disease 12: 871 (2021). [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 18/900,196, dated Feb. 28, 2025. [cited by applicant]
Chiricozzi et al., “Targeting IL-4 for the Treatment of Atopic Dermatitis,” Immunotargets Ther. 9:151-156. (2020). [cited by applicant]
Elysium Health, “What Is Your Skin Barrier, and Why Should You Protect It?” p. 1-13. Retrieved from the Internet: URL: https://www.elysiumhealth.com/blogs/aging101/what-is-the-skin-barrier, 2020. [cited by applicant]
Feng et al., “JD419, a [cited by applicant]
Peng et al., “Identifying the Potential Therapeutic Targets for Atopic Dermatitis Through the Immune Infiltration Analysis and Construction of a ceRNA Network,” Clin. Cosmet. Investig. Dermatol. 14:437-453. (2021). [cited by applicant]
U.S. Appl. No. 18/900,196, filed Sep. 27, 2024. [cited by applicant]
Non-Final Office Action in US 18/900, 196, dated Jul. 22, 2025. [cited by applicant]
Staneva et al., “Haberlea rhodopensis Extract Tunes the Cellular Response to Stress by Modulating DNA Damage, Redox Components, and Gene Expression,” International Journal of Molecular Sciences 24(21):15964 (2023). [cited by applicant]
Dell'Acqua et al., “Skin benefits of a myconoside-rich extract from resurrection plant Haberlea rhodopensis,” [cited by applicant]